Department of Medical Informatics, Erasmus University Medical Center, Suite Ee 21.55, Dr Molewaterplein 50, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
Eur J Pediatr. 2011 Jan;170(1):81-92. doi: 10.1007/s00431-010-1275-7. Epub 2010 Sep 2.
Asthma drugs are amongst the most frequently used drugs in childhood, but international comparisons on type and indication of use are lacking. The aim of this study was to describe asthma drug use in children with and without asthma in the Netherlands (NL), Italy (IT), and the United Kingdom (UK). We conducted a retrospective analysis of outpatient medical records of children 0-18 years from 1 January 2000 until 31 December 2005. For all children, prescription rates of asthma drugs were studied by country, age, asthma diagnosis, and off-label status. One-year prevalence rates were calculated per 100 children per patient-year (PY). The cohort consisted of 671,831 children of whom 49,442 had been diagnosed with asthma at any time during follow-up. ß2-mimetics and inhaled steroids were the most frequently prescribed asthma drug classes in NL (4.9 and 4.1/100 PY), the UK (8.7 and 5.3/100 PY) and IT (7.2 and 16.2/100 PY), respectively. Xanthines, anticholinergics, leukotriene receptor antagonists, and anti-allergics were prescribed in less than one child per 100 per year. In patients without asthma, ß2-mimetics were used most frequently. Country differences were highest for steroids, (Italy highest), and for ß2-mimetics (the UK highest). Off-label use was low, and most pronounced for ß2-mimetics in children <18 months (IT) and combined ß2-mimetics + anticholinergics in children <6 years (NL).
This study shows that among all asthma drugs, ß2-mimetics and inhaled steroids are most often used, also in children without asthma, and with large variability between countries. Linking multi-country databases allows us to study country specific pediatric drug use in a systematic manner without being hampered by methodological differences. This study underlines the potency of healthcare databases in rapidly providing data on pediatric drug use and possibly safety.
哮喘药物是儿童最常使用的药物之一,但国际间关于使用类型和指征的比较尚缺乏。本研究的目的是描述荷兰(NL)、意大利(IT)和英国(UK)儿童中哮喘和非哮喘患者的哮喘药物使用情况。我们对 2000 年 1 月 1 日至 2005 年 12 月 31 日期间的门诊病历进行了回顾性分析。根据国家、年龄、哮喘诊断和标签外使用情况,对所有儿童的哮喘药物处方率进行了研究。每 100 名儿童每年每患者(PY)计算一年的流行率。该队列包括 671,831 名儿童,其中 49,442 名儿童在随访期间的任何时候被诊断为哮喘。β2-激动剂和吸入性皮质类固醇是 NL(4.9 和 4.1/100 PY)、UK(8.7 和 5.3/100 PY)和 IT(7.2 和 16.2/100 PY)中最常开的哮喘药物类别。黄嘌呤、抗胆碱能药、白三烯受体拮抗剂和抗变态反应药的处方量每年每 100 名儿童不到 1 名。在非哮喘患者中,β2-激动剂使用最频繁。各国之间的差异最大的是皮质类固醇(意大利最高)和β2-激动剂(英国最高)。标签外使用率较低,在 18 个月以下的儿童中β2-激动剂(意大利)和 6 岁以下的儿童中β2-激动剂+抗胆碱能药(NL)的标签外使用率最高。
本研究表明,在所有哮喘药物中,β2-激动剂和吸入性皮质类固醇是最常用的药物,在非哮喘儿童中也是如此,而且各国之间的差异很大。连接多国数据库使我们能够以系统的方式研究特定国家的儿科药物使用情况,而不会受到方法学差异的影响。本研究强调了医疗保健数据库在快速提供儿科药物使用和可能的安全性数据方面的作用。